Prana Biotechnology Limited
(ASX:PBT) is set to commence its phase II trial testing with PBT2, the company’s drug in development for Alzheimer’s Disease.
41 patients have been enrolled in the double-blind placebo controlled study based in Melbourne.
The biotech’s Executive Chairman is confident the trial will provide further evidence of PBT2’s positive impact on the brain to assist Alzheimer’s patients.
The disease along with dementia affects aver 26 million people worldwide.
In the 2012 financial year, Prana Biotech booked a net loss of $5.2 million.
